<unk>  is a CC chemokine receptor type 4 (CCR4)-directed monoclonal antibody that is FDA approved for the treatment of adult patients with relapsed or refractory mycosis fungoides or Sézary syndrome after at least one prior systemic therapy.   Common adverse reactions include rash, infusion reactions, fatigue, diarrhea, musculoskeletal pain, and upper respiratory tract infection.
Mogamulizumab
Motavizumab
Tildrakizumab
Risankizumab
Caplacizumab
Ravulizumab
Ixekizumab
Idarucizumab